Compare Biocon with Suven Life Sciences - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs SUVEN LIFE SCIENCES - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON SUVEN LIFE SCIENCES BIOCON /
SUVEN LIFE SCIENCES
 
P/E (TTM) x 31.8 -93.7 - View Chart
P/BV x 3.8 1.5 257.9% View Chart
Dividend Yield % 0.3 1.6 16.6%  

Financials

 BIOCON    SUVEN LIFE SCIENCES
EQUITY SHARE DATA
    BIOCON
Mar-19
SUVEN LIFE SCIENCES
Mar-19
BIOCON /
SUVEN LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs707338 209.4%   
Low Rs554169 326.9%   
Sales per share (Unadj.) Rs91.952.1 176.3%  
Earnings per share (Unadj.) Rs16.76.8 244.6%  
Cash flow per share (Unadj.) Rs24.28.6 282.1%  
Dividends per share (Unadj.) Rs1.001.50 66.7%  
Dividend yield (eoy) %0.20.6 26.8%  
Book value per share (Unadj.) Rs101.665.3 155.7%  
Shares outstanding (eoy) m600.00127.28 471.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.94.9 141.1%   
Avg P/E ratio x37.737.1 101.7%  
P/CF ratio (eoy) x26.129.6 88.2%  
Price / Book Value ratio x6.23.9 159.8%  
Dividend payout %6.022.0 27.3%   
Avg Mkt Cap Rs m378,33032,272 1,172.3%   
No. of employees `0006.11.1 566.6%   
Total wages/salary Rs m11,653661 1,762.4%   
Avg. sales/employee Rs Th8,994.36,132.2 146.7%   
Avg. wages/employee Rs Th1,900.7611.1 311.0%   
Avg. net profit/employee Rs Th1,635.3803.5 203.5%   
INCOME DATA
Net Sales Rs m55,1446,635 831.1%  
Other income Rs m1,444242 596.0%   
Total revenues Rs m56,5886,877 822.8%   
Gross profit Rs m15,8831,604 990.1%  
Depreciation Rs m4,478221 2,022.6%   
Interest Rs m70938 1,880.6%   
Profit before tax Rs m12,1401,587 764.8%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,123718 295.7%   
Profit after tax Rs m10,026869 1,153.2%  
Gross profit margin %28.824.2 119.1%  
Effective tax rate %17.545.2 38.7%   
Net profit margin %18.213.1 138.8%  
BALANCE SHEET DATA
Current assets Rs m48,2286,232 773.9%   
Current liabilities Rs m30,3761,490 2,038.5%   
Net working cap to sales %32.471.5 45.3%  
Current ratio x1.64.2 38.0%  
Inventory Days Days6886 79.0%  
Debtors Days Days8683 103.5%  
Net fixed assets Rs m64,1304,043 1,586.1%   
Share capital Rs m3,000127 2,356.6%   
"Free" reserves Rs m57,9808,183 708.6%   
Net worth Rs m60,9808,310 733.8%   
Long term debt Rs m15,76618 88,573.0%   
Total assets Rs m121,92410,389 1,173.6%  
Interest coverage x18.143.1 42.0%   
Debt to equity ratio x0.30 12,070.1%  
Sales to assets ratio x0.50.6 70.8%   
Return on assets %8.88.7 100.8%  
Return on equity %16.410.5 157.1%  
Return on capital %16.819.5 85.9%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,5065,622 275.8%   
Fx outflow Rs m10,3991,799 577.9%   
Net fx Rs m5,1073,822 133.6%   
CASH FLOW
From Operations Rs m11,546356 3,247.8%  
From Investments Rs m-7,138-279 2,562.1%  
From Financial Activity Rs m-2,417-225 1,073.7%  
Net Cashflow Rs m2,103-148 -1,419.0%  

Share Holding

Indian Promoters % 40.4 63.4 63.7%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 0.0 -  
FIIs % 10.7 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 36.5 54.5%  
Shareholders   109,995 37,287 295.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   NATCO PHARMA  PANACEA BIOTECH  FDC  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare BIOCON With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

TRAI Data for February, Siemens March Quarter Performance, and Buzzing Stocks Today(Pre-Open)

Indian share markets witnessed selling pressure on Wednesday and ended lower.

Related Views on News

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

More Views on News

Most Popular

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

The Worst Sector in the Market(Fast Profits Daily)

May 11, 2021

The worst sector in the stock market according to the charts.

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


May 12, 2021 (Close)

TRACK BIOCON

BIOCON - STRIDES PHARMA SCIENCE COMPARISON

COMPARE BIOCON WITH

MARKET STATS